Results 101 to 110 of about 46,198 (239)
Objectives To describe long‐term outcome and owner‐perceived quality of life in dogs with cyanotic congenital cardiac disease undergoing modified Blalock–Taussig–Thomas shunt procedure. Materials and Methods Medical records of dogs that underwent Blalock–Taussig–Thomas shunt between 2009 and 2025 at a small animal referral hospital were retrospectively
M. Rossanese, J. Hannabuss, D. Brockman
wiley +1 more source
Molecular Links Between Heat Stress and DNA Damage Response in Plants
ABSTRACT Climate change poses a major threat to agricultural productivity and, consequently, to global food security. Among the consequences of climate change, heat stress (HS) has emerged as a critical factor limiting crop performance. This has stimulated extensive research over the past decade to elucidate the molecular and physiological mechanisms ...
Adrian Calves‐Ubach +1 more
wiley +1 more source
Hydroxyurea Therapy in Thalassemiaa
Abstract: The clinical effectiveness of Hydroxyurea in thalassemia is still controversial. The present paper puts together the authors' experience in two groups of patients with thalassemia intermedia and sickle cell/β‐thalassemia treated with varying dosages of hydroxyurea over several months. A third group received hydroxyurea along with recombinant
Loukopoulos, D. +8 more
openaire +3 more sources
Background: To compare hydroxyurea plus iron chelation therapy with iron chelation therapy alone in controlling iron overload in children with beta thalassaemia major.
Tatheer Zahra +2 more
doaj
Abstract Background Chronic automated red cell exchange (RCE) reduces hemoglobin S (HbS) in patients with sickle cell disease (SCD), but procedural success varies across patients in ways standard exchange parameters do not explain. We introduce the Sickling Pressure Index (SPI), derived from each patient's daily rate of HbS rise (ROR) and daily rate of
Austin Choi +3 more
wiley +1 more source
Qualitative Analysis of Hydroxyurea
Hydroxyurea (HU) is a cytostatic agent with antineoplastic activity and it has great clinical efficacy in the treatment of sickle cell disease. HU is part of the National Relation of Essential Medicines of Brazil and despite of its clinical importance, only the Portuguese, American and European Pharmacopoeias present monographs for this medicine.
Santos, Stéfanno Souza +3 more
openaire +8 more sources
Hydroxyurea induces the eNOS-cGMP pathway in endothelial cells
Hydroxyurea is a cell-cycle-specific drug that has been used to treat myeloproliferative diseases and sickle cell anemia. We have recently shown that hydroxyurea, like nitric oxide (NO)-donor compounds, increased cGMP levels in human erythroid cells.
Stojilković, Stanko S. +6 more
core +1 more source
Toxoplasma gondii, Leishmania amazonensis and Trypanosoma cruzi are obligate intracellular parasites that multiply until lysis of host cells. The present study was undertaken to evaluate the effect of hydroxyurea (an inhibitor of cell division at the G1 ...
E.J.T. Melo, H.J. Beiral
doaj +1 more source
ABSTRACT Although circulating nucleated red blood cells (cNRBCs) have previously been detected in patients with sickle cell disease (SCD), their prevalence and clinical significance during steady‐state disease have not been established. We retrospectively analyzed 270 adults with an SS or Sβ0‐thalassemia genotype.
Ugo Boccadifuoco +7 more
wiley +1 more source
ABSTRACT Thrombocytapheresis is an established adjunctive therapy for rapid platelet cytoreduction in patients with extreme thrombocytosis, particularly in myeloproliferative neoplasms (MPNs), where it is typically used alongside cytoreductive pharmacotherapy. Real‐world longitudinal data describing utilization, effectiveness, and safety remain limited.
Homayemem K. Weli +2 more
wiley +1 more source

